Authors: Yuji Kawaguchi, Shoko Miyamoto, Yuriko Hajika, Narumi Ashida, Tomoe Hirota, Koji Masumoto, Jun Sawa, Kenji Hamazaki & Yasuro Kumeda
Abstract
Introduction
We aimed to compare the efficacy of insulin degludec/insulin aspart (IDegAsp) and insulin degludec/liraglutide (IDegLira) in controlling glucose fluctuation and suppressing postprandial glucose levels using intermittently scanned continuous glucose monitoring.
Methods
Twenty-four patients with type 2 diabetes mellitus were randomly allocated to receive either IDegLira or IDegAsp followed by IDegAsp or IDegLira, respectively. A crossover study was conducted with intermittently scanned continuous glucose monitoring. We compared the postprandial blood glucose level, time in range, and time below range from a 3-day intermittently scanned continuous glucose monitoring period for each treatment group.
Results
The time in range was significantly higher in IDegLira than in IDegAsp. Postprandial glucose levels 90 and 120 min after breakfast and 60, 90, and 120 min after lunch were significantly lower for IDegLira than for IDegAsp. However, postprandial glucose levels 90 and 120 min after supper were significantly lower for IDegAsp than for IDegLira. There was no significant difference in the time below range between IDegLira and IDegAsp.
Conclusion
IDegLira was more effective in treating type 2 diabetes mellitus than IDegAsp, as indicated by a higher time in range and lower postprandial glucose level at breakfast and lunch. This study was registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN 000039221).
Key Summary Points |
Why carry out this study?Basal-supported oral therapy has three unmet medical needs: hypoglycemia, weight gain, and glycemic control. Intensive insulin therapy is sometimes needed but patients are burdened by the high number of injections. This study aimed to compare the efficacy of IDegAsp and IDegLira in controlling glycemic variability and suppressing hypoglycemia. |
What was learned from the study?IDegLira had a higher time in range (70–180 mg/dL) than IDegAsp. IDegLira had a lower glucose variability curve after breakfast and lunch than IDegAsp. |